151 492

Cited 0 times in

Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials.

DC FieldValueLanguage
dc.contributor.author김찬-
dc.contributor.author김혜련-
dc.contributor.author노성훈-
dc.contributor.author라선영-
dc.contributor.author안정련-
dc.contributor.author임종근-
dc.contributor.author전홍재-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.contributor.author홍민희-
dc.date.accessioned2015-04-24T17:35:20Z-
dc.date.available2015-04-24T17:35:20Z-
dc.date.issued2009-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105686-
dc.description.abstractPURPOSE: This is an ad hoc analysis of two phase II studies which compared the efficacy and safety of two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced gastric cancer. MATERIALS AND METHODS: Patients with advanced gastric adenocarcinoma who were untreated or had only received first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m(2)) or docetaxel (DFL; 75 mg/m(2)) on day 1, followed by a bolus of LV (20 mg/m(2) days 1~3) and a 24-hour infusion of 5-FU (1,000 mg/m(2) days 1~3) every 3 weeks. The primary endpoint was overall response rate (ORR) and the secondary endpoint included survival and toxicity. RESULTS: Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months, the progression free survival was 5.2 months (95% confidence interval [CI], 4.2~6.5 months) for DFL and 3.3 months (95% CI, 1.3~5.5 months) for PFL (p=0.17). The overall survival was also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2~12.5 months] and 13.9 months [95% CI, 10.9~19.2 months], respectively; p=0.37). The most frequent grade 3~4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had different non-hematologic toxicities; specifically, grade >or=3 mucositis (5%) and diarrhea (3%) were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were common in PFL. CONCLUSION: Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but different toxicity profiles. Prospective comparative studies are required to further clarify the role of taxanes in the treatment of advanced gastric cancer-
dc.description.statementOfResponsibilityopen-
dc.format.extent196~204-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleDocetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHong Jae Chon-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorChong Kun Im-
dc.contributor.googleauthorChan Kim-
dc.contributor.googleauthorMin Hee Hong-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorJung Ryun An-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorHei-Cheul Jeung-
dc.identifier.doi10.4143/crt.2009.41.4.196-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01034-
dc.contributor.localIdA01166-
dc.contributor.localIdA01281-
dc.contributor.localIdA02256-
dc.contributor.localIdA03402-
dc.contributor.localIdA03565-
dc.contributor.localIdA03773-
dc.contributor.localIdA04393-
dc.contributor.localIdA03794-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid20057964-
dc.subject.keywordDocetaxel-
dc.subject.keywordPaclitaxel-
dc.subject.keywordStomach neoplasms-
dc.contributor.alternativeNameKim, Chan-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameAhn, Jung Ryun-
dc.contributor.alternativeNameIm, Chong Kun-
dc.contributor.alternativeNameChon, Hong Jae-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.alternativeNameHong, Min Hee-
dc.contributor.affiliatedAuthorKim, Chan-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorAhn, Jung Ryun-
dc.contributor.affiliatedAuthorIm, Chong Kun-
dc.contributor.affiliatedAuthorChon, Hong Jae-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorHong, Min Hee-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.citation.volume41-
dc.citation.number4-
dc.citation.startPage196-
dc.citation.endPage204-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.41(4) : 196-204, 2009-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.